Malaxinic acid (MA) is a phenolic acid compound, found mainly in pear fruits (Pyrus pyrifolia N.), that is isoprenylated on the C-3 position of benzoic acid. Recently, the effects of prenylated phenolics on health have received much interest owing to their reported potent beneficial biological effects. We conducted a comparative study in rats to determine the metabolism, pharmacokinetics, and antioxidative activities of MA and its corresponding aglycone (MAA). MA and MAA were orally administered to rats (Sprague-Dawley, male, 6 weeks old) and their metabolites in plasma were analyzed. In addition, the MA metabolites in plasma were separated and the structures were confirmed via NMR and HR-MS analyses. The antioxidative activities of MA and MAA were evaluated by measuring their inhibitory effects on the 2,2′-azobis(2-amidinopropane)dihydrochloride-or copper ion-induced lipid peroxidation of rat plasma. MA was not absorbed in the intact form (the glucoside); both MA and MAA were absorbed as MAA and its metabolite form (glucuronide or sulfate). Moreover, the observed metabolite was the glucuronate of MAA rather than the glucuronide or sulfate. Concentrations of the free form of aglycone (MA administration, 4.6 ± 2.2 μM; MAA administration, 7.2 ± 2.3 μM) and total MAA (MA administration, 19.6 ± 4.4 μM; MAA administration, 21.7 ± 3.3 μM) in plasma reached a maximum at 15 min after the oral administration of MA and MAA, respectively. The relative inhibitory effects on the formation of cholesteryl ester hydroperoxides in plasma collected at 15 min after the oral administration of MA, MAA, and p-hydroxybenzoic acid (p-HBA) were as follows: MAA > MA ≥ p-HBA > control. Although the majority of MA and MAA is metabolized to conjugates, the compounds may contribute to the antioxidant defenses in the blood circulation owing to the presence of a phenolic hydroxyl group in the free form.
Introduction
Malaxinic acid [4-(O-β-D-glucopyranosyl)-3-(3′-methyl-2′-butenyl) benzoic acid (MA, Fig. 1 )] is a glucosidic compound connected by an ether bond between β-glucose and 4-hydroxy-3-(3′-methyl-2′-butenyl) benzoic acid (MA aglycone, MAA), which is isoprenylated at the C-3 position of benzoic acid. MA has been isolated from Prunus species [1] and almond hull [2] and was identified in a previous investigation on the antioxidative active compounds present in pears (Pyrus pyrifolia N.) [3] . Asian pear fruits have an MA content of 1-6 mg/100 g fresh weight [3] ; however, the corresponding aglycone (MAA) was not found in the pear fruits [4] . The isolation of MAA was recently reported from Piper species [5] and propolis [6] . Pharmacokinetic and metabolic studies on phenolic compounds including flavonoids and phenylpropanoids have been performed [7] [8] [9] [10] [11] . Studies on the absorption and metabolism of compounds present in food are very important because their structural differences affect bioavailability and bioactivity in vivo. MAA has been reported to exert various biological effects, such as HeLa cell cycle inhibition [12] and antifungal [13] and antibacterial [6] activities. However, the bioactivity of the glucoside form, MA, has not yet been studied. In addition, studies on the absorption and metabolism of MA and MAA have not been conducted.
As described above, MA and MAA contain an isoprenyl group as part of their structure. The isoprenyl group is a starting compound for the biosynthesis of terpenoids. In addition, isoprenyl group is bound to various phenolic compounds [14] [15] [16] [17] [18] including MA and MAA as an intermediate structure. The effects of prenylated phenolic compounds on human health have been thoroughly investigated in recent years because they have been reported to exert potent beneficial antioxidant, antibacterial, and estrogenic activities [15, 19] . A study on the pharmacokinetics of quercetin and 8-isoprenylquercetin in Caco-2 cells showed enhanced cellular uptake of the isoprenylated compound, which was attributed to an increase in lipophilicity; however, in the accompanying in vivo study in rats, the bioavailability of the isoprenylated compound diminished [14] . Therefore, the introduction of the isoprenyl group to phenolic compounds may alter their in vivo bioavailability and bioactivity.
Therefore, by studying the absorption and metabolism of MA and MAA we may be able to elucidate their biological applications, and those of other isoprenylated phenolic compounds in vivo. Standards preparations of MA and MAA are not commercially available and the supply of large-scale, high purity plant sources is also limited [1] [2] [3] [4] [5] [6] . Therefore, in the present study, we chemically synthesized MA and MAA [20] . Our objective was to compare the metabolism, pharmacokinetics, and antioxidative activities of MA and MAA in rat plasma following a single administration of the compounds.
Materials and methods

General experimental procedures
Column chromatography was performed with silica gel resin (Kieselgel 60, 70-230 mesh; Merck, Darmstadt, Germany). Nuclear magnetic resonance (NMR) spectral data were recorded in CD 3 OD (Acros Organics, New Jersey, USA) by Varian unity INOVA 500 and unity INOVA 600 spectrometers (Varian, Walnut Creek, CA, USA) using tetramethylsilane as an internal standard (Acros Organics, New Jersey, USA).
Chemicals
Ethyl-p-hydroxyl benzoate, 1-bromo-3-methyl-2-butene, acetobromo-α-D-glucose, propylene glycol, p-hydroxybenzoic acid (p-HBA), 2,6-di-tert-butyl-4-methyl-phenol (BHT), β-glucuronidase type H-1 (from Helix pomatia, EC 3.2.1.31), D-saccharic acid 1,4-lactone, and α-tocopherol (α-Toc) were purchased from Sigma Chemical Co. (St. Louis, USA). Copper (II) sulfate (CuSO 4 ) and 2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH) were purchased from Wako Pure Chemicals (Osaka, Japan). All other chemicals and solvents were HPLC grade.
Chemical synthesis of MAA and MA
The synthesis of MAA was conducted using the modified method described by Kim et al. [12] . First, ethyl 4-hydroxybenzoate was reacted under the conditions indicated in Scheme 1. Ethyl 4-hydroxybenzoate (exactly 7 g; 0.04 mol) and 1 g sodium (0.04 mol) were added to dry toluene (130 mL) and the mixture was stirred for 5 h at 120°C. 1-Bromo-3-methyl-2-butene (7 mL) was added slowly to the mixture and then stirred successively for 15 h at room temperature and 30 min at 50°C. After filtration, the organic layer was evaporated in vacuo at 35°C. The concentrate was purified using silica gel (Kieselgel 60, Darmstadt, 2.5 × 85 cm, n-hexane/EtOAc = 2:0.5, v/v) column chromatography. The synthetic compound was identified as ethyl 4-hydroxy-3-(3′-methyl-2′-butenyl)benzoate (EHMB) via 1 H NMR analysis. Subsequently, EHMB (600 mg) was added to 0.1 N NaOH (200 mL) and the mixture was stirred for 2 h at 70°C. After cooling to room temperature, the solution (200 mL) was acidified to pH 3.0 with dilute hydrochloric acid solution and partitioned three times with ethyl acetate (EtOAc; 200 mL) to yield MAA. After concentration, the structure of the concentrated compound was confirmed using 1 H NMR spectroscopy and ESI-MS.
In addition, EHMB was dissolved in acetone (60 mL), mixed with acetobromo-α-D-glucose (4.38 g) and 1 N NaOH (10.65 mL), and stirred for 2 h at room temperature. Then, the solution was stirred again for 2 h at 70°C and cooled to room temperature. The solution (70.65 mL) was acidified to pH 3.0 with diluted hydrochloric acid solution and partitioned three times with EtOAc (200 mL). The EtOAc layers were concentrated and purified using silica gel column chromatography (Kieselgel 60, Darmstadt, 2.5 × 91 cm, EtOAc/CHCl 3 /EtOH = 1:1:0. 
Animals and administration of MA and MAA
All experimental procedures were approved by the Institutional Animal Care and Use Committee of Chonnam National University (no. CNU IACUC-YB-2013-54). Six-week-old Sprague-Dawley male rats weighing 180-200 g were supplied by Samtako Bio Korea (Osan, Korea). The animals were kept in an environmentally controlled animal facility with a 12 h dark/light cycle at 20 ± 1°C and 55 ± 5% humidity with free access to distilled water and normal feed (Harlan Rodent diet, 2018S, Samtako Bio Korea). The rats were acclimatized to the environment for 1 day before the experiments commenced. Prior to compound administration, all rats were fasted for 15 h and deprived of water for 3 h. MA and MAA were dissolved in propylene glycol (1 mL) and then orally administered at 50 μmol/kg body weight (MA, 18.4 mg; MAA, 10.3 mg). Before (control) and 15, 30, 60, 120, 240, 480 min after administration, blood was withdrawn from the abdominal aorta of rats under light anesthesia with diethyl ether and placed into heparinized tubes. Plasma was obtained via centrifugation (5000 rpm, 10 min, 4°C) and stored at -80°C until use.
Determination of MA and MAA in rat plasma
MA and MAA were analyzed via HPLC after extraction from the blood plasma. Plasma (200 μL) was mixed with of 0.1 M pH 5.0 sodium acetate buffer (200 μL) and a 19:1 (v/v) mixture of methanol/acetic acid (500 μL). The mixture was vortexed for 30 s, sonicated for 30 s, and centrifuged (5000 rpm, 10 min, 4°C). The supernatant was collected and the residue was mixed with a 19:1 (v/v) mixture of acetone/ acetic acid (500 μL), vortexed, sonicated, and centrifuged as mentioned before. After centrifugation, the supernatants were collected, concentrated, and dissolved in 2% acetic acid aqueous solution (1 mL). The acidic aqueous solution was extracted three times with an equal volume Rat plasma (200 μL) was treated with β-glucuronidase type H-1 (400 units; 200 μL) in 0.1 M pH 5.0 sodium acetate buffer in the absence or presence of 300 mM D-saccharic acid 1,4-lactone and incubated at 37°C for 1 h [21] . The reaction mixtures were extracted using the same procedure as described above.
LC-ESI-MS analysis of MA, MAA, and metabolites in rat plasma
Spectral data were obtained via ESI-MS (API 3200Q trap, Applied Biosystems, Foster City, CA, USA) equipped with an HPLC column (Agilent 1100 series; Agilent, Santa Clara, CA, USA). Separation was performed on a C18 column (MG III, 3 µm, 2.0 × 100 mm, Shiseido, Tokyo, Japan) maintained at 40°C with a flow rate of 1.0 mL/min. The mobile phase consisted of (A) 10% MeCN containing 2% AcOH and (B) 60% MeCN. The elution was started at 0% B, increased to 60% B for 15 min, 70% B for 25 min, and 100% B for 26 min, and finally maintained at 100% B for 45 min. The mass spectrometer was operated in the negative ion mode, and the optimal ion source parameters were as follows: scanning range, m/z 100-800; heat block temperature, 365°C; nebulizing gas, 40 psi; drying gas flow, 9 L/min.
Purification and structural determination of MA metabolite in rat blood plasma after MA administration
Fifteen minutes after the oral administration of MA, plasma (200 mL) was collected from 50 rats and acidified with AcOH (5 mL). The mixture was extracted three times with EtOAc (200 mL), and the EtOAc layers were collected and concentrated. The concentrate was dissolved in MeOH (2 mL) and centrifuged (5000 rpm, 10 min, 4°C). The supernatant was injected onto an HPLC column (μBondapak C 18 , 7.8 × 300 mm, Waters, MA, USA) to separate the MA metabolite. The flow rate was 5.0 mL/min. When the main peak product appeared, the chromatogram was fractionated and immediately loaded onto a reversed-phase solid-phase extraction cartridge (Sep-Pak Vac 35 cc, Waters, MA, USA). The cartridge was conditioned with H 2 O adjusted to pH 2.65 by using trifluoroacetic acid, and eluted with 70 mL of 20%, 30%, 40%, 50%, and 100% MeOH, separately. The 30% MeOH fraction was concentrated and the structure of the MA metabolite was confirmed using NMR and HR-MS analyses. The HR-MS spectrum was acquired on a Synapt G2 quadrupole time-of-flight mass spectrometer equipped with an electrospray ion source (Waters, Milford, MA, USA). The instrument was calibrated using NaF solution. Samples dissolved in MeOH were directly infused into the ion source operating in either positive ion or negative ion mode. All spectra were acquired in the range 50-1500 m/z. Leucine enkephalin was used as the lock mass for accurate mass measurement correction.
Determination of the inhibitory effects of MA and MAA against lipid peroxidation of rat blood plasma induced by radical generator or copper ion
The antioxidative activities of MA and MAA were evaluated by measuring their inhibition of cholesteryl ester hydroperoxide (CE-OOH) formation in hydrophilic radical generator, AAPH-or copper ion-induced oxidation of rat plasma [22] . This experiment was conducted on rat plasma collected at 15 min after oral administration of MA, MAA, and p-HBA (used as a positive control for copper ion-induced oxidation). Blood plasma was diluted four-fold in pH 7.4 phosphate-buffered saline (PBS). The diluted plasma (2160 μL) was oxidized by addition of 240 μL of AAPH-PBS solution (final concentration, 5 mM) or CuSO 4 -PBS solution (final concentration, 100 μM). The mixture was incubated at 37°C for up to 13 h with continuous shaking. The CE-OOH concentration was determined using the method described by Arai et al. [23] . The extracted lipids were dissolved in a 19:1 (v/v) mixture of MeOH/CHCl 3 (100 μL), and the aliquots were subjected to RP-HPLC using a TSK-gel Octyl-80Ts column (4.6 × 150 mm, Tosoh, Tokyo, Japan) to determine the CE-OOH content. The effluent was monitored via UV detection at 235 nm (Shimadzu SPD-10A). MeOH/H 2 O (97:3, v/v) served as the mobile phase and a constant flow rate of 1.0 mL/min was used. The CE-OOH concentration was calculated from a standard curve of CE-OOH; Scheme 1. Synthetic scheme of MA and MAA. EHMB, ethyl 4-hydroxy-3-(3′-methyl-2′-butenyl)benzoate; MA, malaxinic acid; MAA, malaxinic acid aglycone.
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the detailed procedures for the preparation of this curve have been previously published [23] .
Measurement of administered compounds and their metabolites and α-Toc during oxidation of rat plasma
The α-Toc content was determined using the method described by Murase et al. [22] . The plasma extract was dissolved in 100 μL of acetonitrile/H 2 O (95:5, v/v) and injected into TSK-gel Octyl-80Ts column (4.6 × 150 mm, Tosoh, Tokyo, Japan) with acetonitrile/H 2 O (95:5, v/v) as the mobile phase and flow rate of 1.0 mL/min. α-Toc was monitored by fluorescence detection (RF-10A XL , Shimadzu, Kyoto, Japan, excitation at 295 nm; emission at 335 nm).
To determine the residual ratio of MAA and MAA conjugate after oral administration of MA and MAA, plasma aliquot (400 μL) from the incubation system was mixed with 3.6 mL of acetonitrile contained 2.5 mM BHT. The mixture was sonicated for 1 min and centrifuged at 5000 rpm for 15 min. The supernatant was concentrated and dissolved in 100 μL of MeOH. The extract was analyzed by the same HPLC condition as described at Section 2.5.
Statistical analysis
Data are expressed as mean ± standard deviation (SD) using the Statistical Package for Social Sciences (SPSS, IBM, Armonk, NY, USA) 19.0 package program. Statistical differences were measured by oneway analysis of variance followed Tukey-Kramer test. A P < 0.05 was considered significant.
Results
Synthesis of MA and MAA
The synthesized MA and MAA were produced in yields of 57.7% and 94.7%, respectively, and the purities of the both compounds were above 99%. The structures of MA and MAA were determined from the comparison of 1 H NMR spectra to published data [3, 4] (Fig. 2) and MA (Fig. 3) were analyzed via HPLC. Plasma samples from rats administered MAA were compared before ( Fig. 2C) and after (Fig. 2D) β-glucuronidase H-1 treatment. Herein, we displayed the rat plasma data at only 15 min after administration. Standards of MA and MAA were detected at t R 14.8 and 22.9 min, respectively (Fig. 2E) , and peaks that overlapped the standards in the chromatogram of control ( Fig. 2A) were not detected. In rat plasma extracts at 15 min after the administration of MAA, the intact form was detected at t R 22.9 min (Fig. 2C, ▽) . In addition, the peak at t R 18.2 min (Fig. 2C, ▼) , which was considered a metabolite of MAA, was detected in the plasma. The plasma was treated with glucuronidase H-1, which has both sulfatase and glucuronidase activity, and the extract was analyzed using HPLC. Interestingly, the peak at t R 18.2 min (▼) disappeared (Fig. 2D) and was therefore considered a metabolite of MAA. In addition, the area of peak at the equivalent t R of standard MAA showed a greater increase (Fig. 2D ) in comparison with that (Fig. 2C,  ▽) before glucuronidase H-1 treatment. Therefore, the peak ▼ was suggested to be conjugated by glucuronic acid or sulfuric acid to MAA.
Determination of MA and MAA in blood plasma of rats administered MA
The chromatogram of plasma extracts at 15 min after oral administration of MA (Fig. 3C ) was compared to that of the standard compounds (MA and MAA, Fig. 3E ). The HPLC chromatogram of plasma in rats administered MA (Fig. 3C) showed a similar pattern to that of plasma in rats administered MAA (Fig. 2C) . That is, the intact form of MA, the glucoside (Fig. 3C, ↓) , was not detected in the plasma extracts at 15 min after oral administration of MA (Fig. 3C) , or in plasma extracts at all other times after the administration of MA (data not shown). Under these analytical conditions, the limit of detection for MA was 13.5 pmol. In contrast, the peak detected at t R 22.9 min (Fig. 3C,  ▽) was at the equivalent t R as the MAA standard. In addition, similar to the results of the plasma in rats administered MAA, the peak at t R 18.2 min (Fig. 3C, ▼) , which was considered to be a metabolite of MA, was detected in the plasma of rats administered MA. Furthermore, the peak (▼) disappeared after glucuronidase H-1 treatment of plasma from rats administered MA (Fig. 3D) . Therefore, the peak (▼) detected in the plasma of rats administered MA was also suggested to be a conjugated form of MAA.
LC-ESI-MS analyses of plasma from rats administered MA and MAA
After treatment with β-glucuronidase H-1, the peaks (Figs. 2C and 3C, ▼), which were considered to be produced by a metabolite, disappeared in the plasma from rats administered both MA and MAA (Figs. 2D and 3D) . Instead, the area of the peaks at t R 22.9 min (MAA) increased (Figs. 2D and 3D) . Therefore, we repeated the β-glucuronidase H-1 treatment in the presence of D-saccharic acid 1,4-lactone, which is a β-glucuronidase inhibitor [24] , for rats administered MA and MAA, in order to obtain more concrete information about the compound considered a metabolite. The peak areas of the compound thought to be a metabolite of MA and MAA showed no change and the peak areas of MAA were also not changed (data not shown). This [399] [400] [401] [402] [403] [404] [405] [406] [407] suggested that the compound thought to be a metabolite was a glucuronide rather than a sulfate. In addition, the plasma extracts collected at 15 min after the administration of MA that were not treated with β-glucuronidase H-1 were subjected to LC-ESI-MS (negative mode) analysis in order to identify MAA, its metabolite, and the presence or absence of the intact form (MA). No peaks corresponding to the intact form of MA (the glucoside) were detected from the eluent at the same t R (14.8 min) as the MA standard (data not shown). In contrast, the peak (Fig. 3C, ▽) at the same t R (22.9 min) as the MAA standard showed a molecular ion peak [M-H] -at m/z 204.7 that was assigned to MAA (Fig. 4A ). In addition, the mass spectrum of the metabolite peak (Fig. 3C, ▼) showed a molecular ion peak [M-H] -at m/z 380.7 that was identical to the glucuronide of MAA (Fig. 4B) . Additionally, the plasma extracts at 15 min after administration of MAA that were not treated with β-glucuronidase H-1 (Fig. 2C) were analyzed via LC-ESI-MS (negative mode). The presence of MAA (Fig. 2C , ▽) and its glucuronide (Fig. 2C , ▼) were also clearly confirmed (data not shown). These findings strongly suggested that orally administered MA and MAA were absorbed into the blood as the aglycone and metabolite (glucuronide) forms, but not the glucoside or sulfate forms. 13 C NMR spectra of the MA metabolites were similar to those of MA, except for the glucuronic acid moiety [3] . The β-D-glucuronic acid moiety was confirmed by the presence of an anomeric proton signal at δ Fig. 2 . HPLC chromatograms of rat plasma extracts after oral administration of MAA (10.3 mg/kg body weight (Fig. 5, arrows) . In particular, the correlation of H-2, H-6, and H-1″ to C-7 in the HMBC spectrum confirmed that glucuronic acid was esterified to 3-(3′-methyl-2′-butenyl)-4-hydroxybenzoic acid. Therefore, the structure of the MA metabolite was determined to be 7-O-β-D-glucuronoyl 3-(3′-methyl-2′-butenyl)-4-hydroxybenzoate (Fig. 5 ).
Structural determination of MA metabolite by NMR and MS analysis
Pharmacokinetics of total MAA and its metabolite in the plasma of rats administered MA and MAA
The above results confirmed that MA was not absorbed as the intact form (the glucoside) and that both MA and MAA were absorbed as the aglycone and its metabolite (in glucuronate form). Therefore, the plasma extracts from rats administered MA and MAA and treated with or without β-glucuronidase H-1 were analyzed via HPLC in order to study the pharmacokinetics of MAA and total MAA (free form MAA + metabolite) (Figs. 6 and 7) .
The changes in the plasma concentration of the intact form (MAA) and its metabolite following the administration of MAA are shown in Fig. 6 . The intact form was not detected (limit of detection, 13.5 pmol) in plasma at 5 min after administration, reached a maximum concentration (7.2 ± 2.3 μM) at 15 min after administration, and then Fig. 4 . ESI-MS data (negative) of rat plasma extract (without β-glucuronidase H-1 treatment) after oral administration of MA. A, eluted at t R 22.9 min (▽) on HPLC chromatogram shown in Fig. 3C ; B, eluted at t R 18.2 min (▼) on HPLC chromatogram shown in Fig. 3C . MA, malaxinic acid. Values are mean ± SD (n = 3). Different letters indicate significant differences at P < 0.05 assessed using Tukey-Kramer test. MAA, malaxinic acid aglycone. Fig. 7 . The change in total MAA concentration in rat plasma after the oral administration of MA (18.4 mg/kg body weight). Values are means ± SD (n = 3). Different letters indicate significant differences at P < 0.05 assessed using Tukey-Kramer test. MA, malaxinic acid; MAA, malaxinic acid aglycone.
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steadily decreased. In contrast, the metabolite (5.9 ± 2.1 μM) was detected in plasma at 5 min after administration. Furthermore, the concentration of total MAA (21.7 ± 3.3 μM) increased to the highest level at 15 min after administration and slightly decreased at 30 min (12.6 ± 3.2 μM) after administration; subsequently, a rapid decrease was observed. However, the intact form and total MAA were still present, at concentrations of 0.4 ± 1.6 μM and 1.6 ± 1.3 μM, respectively, at 8 h after the administration of MAA. After the administration of MA (the glucoside) (Fig. 7) , the concentration of MAA in the free form in plasma reached the maximum concentration (4.6 ± 2.2 μM) within 15 min of administration, thereafter gradually decreased, but was still present at 8 h after administration (1.1 ± 0.3 μM). The observations were similar to those following the administration of MAA: MAA in the free form was not found in plasma at 5 min after administration of MA, the concentration of total MAA (0.5 ± 0.5 μM) was lower than that in plasma at 5 min after administration of MAA (5.9 ± 2.1 μM), and the concentration of the total MAA in plasma after β-glucuronidase H-1 treatment reached its maximum (19.6 ± 4.4 μM) within 15 min of treatment. The levels declined more slowly than those in the plasma of rats administered MAA.
The concentration of MAA in the free form was highest at 15 min after the administration of MA and MAA, respectively. In the same plasma, the concentration of MAA in the free form in plasma from rats administered MAA was slightly higher (7.2 ± 2.3 μM) than that in plasma from rats administered MA (4.6 ± 2.2 μM) but there was no significant difference (Table 2 ). In addition, regardless of the structure of the administered compounds, the total MAA reached the maximum concentration within 15 min of administration and the concentration was higher in plasma from rats administered MAA (21.7 ± 3.2 μM) than those administered MA (19.6 ± 4.4 μM), but this difference was not significant.
Inhibitory effect against AAPH-or copper ion-induced lipid peroxidation of plasma from rats administered MA and MAA
The inhibitory effect against AAPH-or copper ion-induced lipid peroxidation was compared using rat blood plasmas collected at 15 min after administration of MA and MAA, because the plasma showed the highest absorption in the free and metabolite forms of MAA at this time. Fig. 8 shows the time course of CE-OOH formation and the decrease of α-Toc and metabolites (MAA and MAA glucuronate) after administration of MA and MAA. The decrease of α-Toc was observed to be more delayed in MA and MAA administered groups than in control group, and was more prolonged in MAA administered group than in MA administered group (Fig. 8) . The metabolites after administration of MA and MAA were reduced after α-Toc was depleted, and the reduction of metabolites in MAA administered group was further delayed than in MA administered group (Fig. 8) . MA and MAA administered groups were more effectively inhibited CE-OOH accumulation than control group. In addition, MAA administered group showed higher inhibitory effect on CE-OOH formation than MA administered group (Fig. 8) .
The inhibitory effect against copper ion-induced lipid peroxidation of MA and MAA was compared with that of p-HBA, which does not contain the isoprenyl group that is present in the structure of MAA. Plasma samples after the administration of MA (21.1 ± 0.9 μM), MAA (14.9 ± 2.1 μM), and p-HBA (21.4 ± 1.9 μM) showed greater inhibition of the formation of CE-OOH than control plasma (26.7 ± 1.7 μM) and the effect was higher in plasma from rats administered MAA than those administered MA and p-HBA (Fig. 9) .
The concentrations of free form and total MAA showed higher pattern in plasma from rats administered MAA (7.2 ± 2.3 and 21.7 ± 3.2 μM, respectively) than those in plasma from rats administered MA (4.6 ± 2.2 and 19.6 ± 4.4 μM, respectively). In addition, the plasma from rats administered MAA more efficiently inhibited the formation of CE-OOH than plasma from rats administered MA did (Fig. 9) . Therefore, the inhibitory effect against lipid peroxidation of rat blood plasma might be attributed to presence of MAA in the free form as well as the metabolite form. Table 2 The concentration of MAA (free form) and total MAA (free form + conjugate form) in rat plasma after the oral administration of MA (18.4 mg/kg body weight) and MAA (10.3 mg/kg body weight), respectively. 
Discussion
In nature, the most widely distributed phenolic compounds are flavonoids and phenolic acids [25] . Various phenolic compounds including flavonoids, caffeic acid, ferulic acid, and chlorogenic acid have been extensively studied in recent years owing to their reported biological activities [7] [8] [9] [10] [11] . During an investigation on the antioxidative compounds in pear [3, [26] [27] [28] [29] [30] [31] [32] [33] , we isolated MA as one of the major components [3] , along with various other flavonoids and phenolic acids. The compound MAA has been reported to inhibit HeLa cell cycle progression [13] , and it was suggested that the isoprenyl side chain may contribute to inhibition of a 21-26 kDa protein involved in the proliferation of cancer cells [34] . A considerable portion of the phenolic compounds present in plants exists as glycosides [35] . However, they are mainly absorbed in their conjugated forms, such as sulfate and/or glucuronide, after hydrolysis in vivo, except for a small number of special cases such as anthocyanin [24, 25, [36] [37] [38] [39] . Therefore, in vivo biological activity may be dependent on the form of the metabolites. The MA in pear is present as a glucoside [4] . Nevertheless, the biological activity for the MA glucoside has not yet been investigated, nor has the metabolic difference between MA and MAA been assessed. Therefore, in the present study, we carried out a comparison of metabolism, pharmacokinetics, and antioxidative activity between MA and MAA in rats.
We analyzed the blood plasma of rats at 15 min after oral administration of MA and MAA via HPLC to confirm the presence or absence of intact and/or metabolic forms. We conducted analyses at this time point because, after administration of MAA, the highest concentration level of compounds related to MAA were found.
All HPLC chromatograms of the rat plasma at 0.25-8 h after administration of MA showed similar patterns to those of plasma from rats administered MAA. That is, it was clarified that MA was not absorbed as the intact form (the glucoside) and that both MA and MAA were absorbed as MAA and its metabolite, regardless of the presence or absence of glucose in the structure.
The concentration of the free form of MAA in plasma from rats administered MA and MAA peaked at 15 min after administration of each compound. According to previous investigations on the adsorption and metabolism of phenolic acids such as ferulic acid, p-coumaric acid, and caffeic acid, the majority of phenolic acids are absorbed through the monocarboxylate transporter (MCT) route [25] . These compounds were detected in the intact form in rat plasma at 5 min after oral administration. The level conjugated form shows a peak at 5 min after oral administration, and the intact and conjugated forms were close to the limit of detection limit at 1 h after oral administration [25] . These phenomena have been understood through the MCT reactions in the stomach [25] . In our study, the pharmacokinetic profile of plasma in rats administered MAA was similar to that of other phenolic acids. However, in rats administered MA, the pharmacokinetic profile was different to that in rats administered MAA; that is, the decrease in the free and conjugate forms of MAA in plasma from rats administered MA was more prolonged than that in the plasma from rats administered MAA. These differences in pharmacokinetic profile might be due to the structural characteristics of the two compounds. MA and MAA have an isoprenyl group in each molecule, which should accelerate intestinal absorption because such binding increases lipophilicity and confers the molecule with a high affinity to the cellular membrane [40] and MCT. In this study, it was suggested that the MCT-mediated absorption system might be involved in the gastric absorption of MA and MAA. As MAA possesses an isoprenyl side chain, which may allow a high affinity to cellular membranes with increase of lipophilicity, and a carboxylic acid group, a portion of MAA might be absorbed more rapidly into the stomach than MA owing to increased reactivity with MCT. A majority of MAA seems to be absorbed in the upper part of small intestine. Alternatively, the absorption rate of MA (the glucoside) in the stomach might be lower than that of MAA owing to a decrease in reactivity between MA and MCT following an increase in hydrophilicity due to the addition of glucose to the MAA structure.
In a previous study on the absorption and metabolism of p-HBA, which does not have an isoprenyl group, sulfuric acid conjugates of the ether type and glucuronides of the ether and ester types were detected from the urine of humans and rabbits administered p-HBA [41] . However, in the present study, only one metabolite was detected. In addition, this metabolite was confirmed as a conjugate connected with glucuronic acid via enzyme treatment, HPLC, and LC-MS. However, the metabolite (Figs. 2C and 3C , t R 18.2 min, ▼) was eluted later than MA (monoglucoside, Figs. 2E and 3E, t R 14.8 min, ↓) in the HPLC analyses using a reversed phase ODS column. After considering the relative polarity of these compounds and the characteristics of the ODS column, it was suggested that the metabolite may be a glucuronate rather than a glucuronide. Consequently, the structure of the metabolite of MA and MAA was unambiguously determined as the glucuronate, and not the glucuronide, by 1D and 2D NMR analyses. This difference between the metabolites of MAA and p-HBA might be attributed to the steric hindrance of the glucuronidation to the p-hydroxyl group by the isoprenyl group from the action of enzyme such as a uridine-5′-diphosphoglucuronosyl transferase, a typical glucuronidation enzyme.
Lipid peroxidation and the products are recognized as important factors in the development of various disorders and diseases such as atherosclerosis and coronary heart disease. In particular, CE-OOH has been used as a biomarker of lipid peroxidation in blood plasma to assess the progression of various pathologic disorders [42] [43] [44] . To evaluate the antioxidant activity of MA and MAA in plasma after oral administration, CE-OOH accumulation was measured. The electron-withdrawing property of the carboxylic acid group in benzoic acids has a negative influence on the H-donating ability of hydroxybenzoic acids and decreases their antioxidant activity [45] . Therefore, we predicted that MAA may exert a low antioxidant activity. However, in our experiments on the inhibition of the AAPH-induced lipid peroxidation in plasma, the consumption of α-Toc was more delayed in MA and MAA administered groups than in control group. This result suggested that the MA and MAA metabolites prolonged the depletion of α-Toc. Moreover, the MA and MAA metabolites were decreased more rapidly after α-Toc disappeared, and metabolites after oral administration of MAA were delayed than those after oral administration of MA. The lipid peroxidation of MA and MAA administered groups was also inhibited than that of control group, and the inhibitory effect was higher in the MAA administered group than MA administered group. Therefore, it was suggested that MA and MAA metabolites may inhibit oxidation of blood plasma.
In addition, the inhibitory effect against copper ion-induced CE-OOH formation of plasma was higher in plasma after administration of MAA in rats (14.9 ± 2.1 μM) than in those after administration of p-HBA (21.4 ± 1.9 μM), MA (21.1 ± 0.9 μM) and the control plasma (26.7 ± 1.7 μM). Therefore, it is believed that MA, as well as MAA, may act as effective antioxidants in blood plasma, although the efficacy of their antioxidative activities were slightly different. In addition, although a majority of MA and MAA is metabolized to conjugates, they may contribute to the antioxidant defense in the blood circulation because of the presence of phenolic hydroxyl group in the free form.
In conclusion, we compared the absorption and metabolism of MA and MAA. MA and MAA were mostly present in blood plasma in a metabolite form (the glucuronate) but some of the aglycone was also present in the free form. In addition, the concentration of MAA in the free and conjugated forms was slightly higher in the plasma of rats administered MAA than in that of rats administered MA, although these differences were not significant. In experiments on the inhibitory effect on the formation of CE-OOH in plasma after the oral administration of MA, MAA, and p-HBA, the plasma collected at 15 min after oral administration of MAA in rats showed higher activity than did plasma from rats administered MA and p-HBA, and the control plasma. Therefore, it was considered that MAA, in addition to MA, would be likely to show antioxidant activity in blood plasma, albeit at different efficacies. In addition, a higher effect may be expected from a greater intake of MAA than MA. Moreover, the long-term intake of MA-and MAA-rich foods such as pear, Prunus species, and propolis may be partly responsible for the elevation of antioxidative activity in the blood circulation with other antioxidative active compounds present in food resources.
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